Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: High-Risk Nevus Phenotype
Interventions: survey, Saliva samples; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more

Conditions: Non-muscle-invasive Bladder Cancer
Interventions: STM-416; Drug
Lead sponsor: SURGE Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Little Rock, Arkansas + 16 more

Conditions: Anorectal Surgeries
Interventions: Epiflo; Device
Lead sponsor: Neogenix, LLC dba Ogenix; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Child Behavior, Parent-Child Relations, Substance Use, Substance Abuse
Interventions: Filming Interactions to Nurture Development, The Healthy Toddler Program; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: Up to 50 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Myeloma
Interventions: Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spine Metastases
Interventions: Prophylactic Radiotherapy, Standard of care systemic therapy; Radiation · Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Cardiac MRI, ACC/AHA Guideline adherent care; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: AIDS-Related-Primary Central Nervous System Lymphoma
Interventions: Methotrexate, Rituximab, Leucovorin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ileal Pouch
Interventions: EXE-346, Placebo; Biological · Other
Lead sponsor: Exegi Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more

Conditions: Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions: ZD6474 (Vandetanib), Carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sleep Disorder; Breathing-Related
Interventions: Not listed
Lead sponsor: Itamar-Medical, Israel; Industry
Eligibility: 17 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Woodland Park, Colorado

Conditions: High Blood Pressure
Interventions: Nebivolol, Metoprolol XL; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia
Interventions: Cytarabine, Idarubicin, Laboratory Biomarker Analysis, Pevonedistat, Pharmacological Study; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • Miami, Florida + 1 more

Conditions: HIV Infections, Dyslipidemia, Endothelial Dysfunction
Interventions: extended release niacin; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Interventions: Melphalan, Bortezomib, Melphalan and bortezomib; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Jacksonville, Florida • Lebanon, New Hampshire

Conditions: Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions: XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor); Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more

Conditions: Neuroblastoma, Pediatric Cancer
Interventions: Cyclophosphamide, Topotecan, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Carboplatin, Mesna; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 19 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Urology
Interventions: Preoperative Outreach; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV, Drug Use
Interventions: Y2Prevent; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 18 Years to 24 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Transient Tachypnea of the Newborn
Interventions: High Flow Nasal Cannula, Bubble Nasal CPAP; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Up to 24 Hours
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Fibrosis
Interventions: placebo, BIBF 1120; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 24
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 20 more

Conditions: Chronic Pain
Interventions: VCPM; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Aurora, Colorado • West Haven, Connecticut

Conditions: High Blood Pressure, Flow Mediated Dilation
Interventions: fruit and vegetable juice supplement, Placebo; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Colon Surgery

A Scaleable Video Coaching Intervention for Opioid-using Mothers

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

WatchPAT Compared to PSG at 8500'

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

XIENCE 28 USA Study

A Study of N9 Chemotherapy in Children With Neuroblastoma

Preoperative Outreach to Improve Surgical Attendance

Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)

High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

Virtual Pain Care Management (COVID-19)

Effect of Nitrate-rich Fruit and Vegetable Supplement on Blood Pressure